David SmithChief Commercial Officer at Healios
David Smith was appointed to a Board Director of HEALIOS K.K. on March 2018, then in July he assumed the position of Chief Commercial Officer (CCO) Of Healios NA, Inc., Healios’ subsidiary in the United States. David is focusing on building global manufacturing strategy as well as supporting Healios’ business development efforts in the US and EU, utilizing his abundant experiences in the field of cell manufacturing.
Previously, Mr. Smith joined Cambrex Bioproducts in 2002 as the Business Unit Director of the emerging cell therapy contract manufacturing business. In 2004, he was promoted to Vice President, Business Development, and in December 2005 to Vice President, Cellular Therapeutics. In this role, he assumed responsibility for contract manufacturing, process development, and clinical/commercial development of Cambrex owned Engineered Skin Substitute (ESS) for catastrophic burns. In 2009, two years following Lonza’s acquisition of Cambrex Bioproducts, Mr. Smith became Head of Therapeutic Cell Solutions; with additional responsibilities for biotherapeutic media, process development, viral vaccines and gene therapies. In 2015, Mr. Smith became Vice President, Global Business Development, focusing on strategic agreements and alliances for the Emerging Technologies Business Unit, which includes cell and viral therapy. He is an active member of numerous government expert panels; company executive committees and advisory boards. Under Mr. Smith leadership the cell therapy contract manufacturing business as grown from start-up to market leader.
Prior to joining Cambrex, Mr. Smith spent 14 years at The Upjohn Company in various sales and marketing roles, including leading the launch of the Parkinson’s therapeutic, Mirapex.
Mr. David Smith holds a B.S. in Pharmacy from Duquesne University in Pittsburgh, Pennsylvania and a M.B.A. from Wheeling Jesuit University in Wheeling, West Virginia